tiprankstipranks
Advertisement
Advertisement
Prothena expects to end year with $255M in cash, equivalents
PremiumThe FlyProthena expects to end year with $255M in cash, equivalents
1M ago
Prothena Earnings Call: Pipeline Progress, Risks Ahead
Premium
Company Announcements
Prothena Earnings Call: Pipeline Progress, Risks Ahead
2M ago
Prothena: Transformative CYTOPE and TfR Platforms Underpin Long‑Term Upside and Support Buy Rating
Premium
Ratings
Prothena: Transformative CYTOPE and TfR Platforms Underpin Long‑Term Upside and Support Buy Rating
2M ago
Prothena price target raised to $8 from $4 at BofA
PremiumThe FlyProthena price target raised to $8 from $4 at BofA
5M ago
Sell Rating for Prothena Due to Reliance on Partnered Programs and Uncertainties in Phase 3 Trials
Premium
Ratings
Sell Rating for Prothena Due to Reliance on Partnered Programs and Uncertainties in Phase 3 Trials
5M ago
Promising Outlook for Prothena: Buy Rating Backed by Innovative CYTOPE Platform Advancements
Premium
Ratings
Promising Outlook for Prothena: Buy Rating Backed by Innovative CYTOPE Platform Advancements
5M ago
Prothena price target raised to $30 from $20 at H.C. Wainwright
PremiumThe FlyProthena price target raised to $30 from $20 at H.C. Wainwright
5M ago
Prothena Corporation’s Q3 2025 Financial and Clinical Updates
Premium
Company Announcements
Prothena Corporation’s Q3 2025 Financial and Clinical Updates
5M ago
Prothena reports Q3 EPS (68c), consensus (54c)
Premium
The Fly
Prothena reports Q3 EPS (68c), consensus (54c)
5M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100